Please assess the completion status of the following clinical trial:

Trial Title: Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In good general health~* Susceptible to human rhinovirus type 16 (HRV-16)~* Male or non-pregnant and non-breast feeding female~* If female of reproductive potential, agrees to use 1 form of acceptable birth control~Exclusion Criteria:~* Donated blood within 56 days or donated plasma within 7 days prior to dosing~* History of significant multiple and/or severe allergies~* Recent history of respiratory tract infection~* History of cancer~* Body mass index \<18 kg/m\^2 or ≥40 kg/m\^2~* History of major surgery or loss of 1 unit of blood~* History of allergic reaction to sulfonamides~* Received medications within 14 days prior to randomization~* Significantly abnormal laboratory tests at Screening~* Current smoker, smoked within 5 years of Screening, or significant past smoking history~* History of alcohol or drug abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Gefapixant 45 mg BID (Type: EXPERIMENTAL): Participants will receive a gefapixant 45 mg tablet twice daily (BID) for 7 days.
- Placebo BID (Type: PLACEBO_COMPARATOR): Participants will receive a matching placebo tablet BID for 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).